Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma

Trial Profile

A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Safusidenib (Primary)
  • Indications Astrocytoma; Glioma; Oligodendroglioma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms G203; SIGMA
  • Sponsors AnHeart Therapeutics; Nuvation Bio

Most Recent Events

  • 11 Nov 2026 According to a Nuvation Bio media release, trial overview will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting taking place November 12 to 15, 2026, in Philadelphia, PA.
  • 29 Oct 2026 According to a Nuvation Bio media release, phase 3 SIGMA study evaluating safusidenib will expand its study sites to the United Kingdom, France, Sweden, Germany, Italy and Spain, in addition to the United States, Australia, China, Canada and Japan, where the study is currently enrolling or expected to begin enrolment
  • 20 Aug 2026 According to Nuvation Bio media release, the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib. If relevant criteria are met, the designation may allow for rolling review of a marketing application, permitting completed sections to be submitted for FDA review as they become available, rather than waiting for the entire application to be complete.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top